Pioglitazone – Do we really need it to manage type 2 diabetes?

Kim, 2011, Thalidomide: the tragedy of birth defects and the effective treatment of disease, Toxicological Sciences, 122, 1, 10.1093/toxsci/kfr088 Gale, 2005, Troglitazone – the lesson that nobody learned, Diabetologia Benbow, 2001, Thiazolidinediones for type 2 diabetes: all Glitazones may exacerbate heart failure, BMJ, 322, 236 Nissen, 2010, Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality, Archives of Internal Medicine, 170, 1191, 10.1001/archinternmed.2010.207 Shah, 2010, Pioglitazone: side effects, safety profile, Expert Opinion on Drug Safety, 9, 347, 10.1517/14740331003623218 2007 Goldberg, 2005, A comparison of lipid and glycemic effects of Pioglitazone and Rosiglitazone in patients with type 2 diabetes and dyslipidemia, Diabetes Care, 28, 1547, 10.2337/diacare.28.7.1547 Nissen, 2008, Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial, JAMA, 299, 1561, 10.1001/jama.299.13.1561 Dormandy, 2005, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial, Lancet, 366, 1279, 10.1016/S0140-6736(05)67528-9 Lincoff, 2007, Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials, JAMA, 298, 1180, 10.1001/jama.298.10.1180 Ryder, 2011, Pioglitazone: an agent which reduces stroke, myocardial infarction and death and is also a key component of the modern paradigm for the optimum management of type 2 diabetes, British Journal of Diabetes and Vascular Disease, 11, 113, 10.1177/1474651411412658 Kannel, 1974, Role of diabetes in congestive heart failure: the Framingham study, American Journal of Cardiology, 34, 29, 10.1016/0002-9149(74)90089-7 Giles, 2008, Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction, Journal of Cardiac Failure, 14, 445, 10.1016/j.cardfail.2008.02.007 Nesto, 2003, Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association, Circulation, 108, 2941, 10.1161/01.CIR.0000103683.99399.7E Richter, 2009, Pioglitazone for type 2 diabetes mellitus, The Cochrane Library Meymeh, 2007, Diabetes drug Pioglitazone (Actos): risk of fracture, CMAJ, 177, 723, 10.1503/cmaj.071177 Meier, 2008, Use of thiazolidindiones and fracture risk, Archives of Internal Medicine, 168, 820, 10.1001/archinte.168.8.820 Loke, 2009, Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis, CMAJ, 180, 32, 10.1503/cmaj.080486 Miyazaki, 2002, Effect of Pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients, Journal of Clinical Endocrinology and Metabolism, 87, 2784, 10.1210/jcem.87.6.8567 Jacob, 2007, Weight gain in type 2 diabetes mellitus, Diabetes, Obesity and Metabolism, 9, 386, 10.1111/j.1463-1326.2006.00622.x Berlie, 2007, Thiazolidinediones and the risk of edema: a meta-analysis, Diabetes Research and Clinical Practice, 76, 279, 10.1016/j.diabres.2006.09.010 Berria, 2007, Reduction in hematocrit and haemoglobin following Pioglitazone treatment is not hemodilutional in type II diabetes mellitus, Clinical Pharmacology and Therapeutics, 82, 275, 10.1038/sj.clpt.6100146 Lewis, 2011, Risk of bladder cancer among diabetic patients treated with Pioglitazone: interim report of a longitudinal cohort study, Diabetes Care, 34, 916, 10.2337/dc10-1068 Piccinni, 2011, Assessing the association of Pioglitazone use and bladder cancer through drug adverse event reporting, Diabetes Care, 34, 1369, 10.2337/dc10-2412 European Medical Agency [22.07.2011], 2011 Azoulay, 2012, The use of Pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case–control study, BMJ, 344, e3645, 10.1136/bmj.e3645